Norton Rose-Led FibroBiologics Plans Direct Listing Over IPO
Chronic-disease-focused drug developer FibroBiologics Inc. said Thursday that its shares will begin trading on Jan. 31 through a direct listing rather than a traditional initial public offering, represented by Norton Rose...To view the full article, register now.
Already a subscriber? Click here to view full article